UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn’s disease
San Diego, CA, USA | May 20, 2008 | UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn’s disease. Data also showed continued remission amongst the majority of responders, and the remission rate remained stable in many of the patients who were re-induced with Cimzia(R). These results represent data from the PRECiSE trial program, which evaluated more than 1,300 patients receiving continuous treatment with Cimzia(R) (400 mg) for up to 18 months.
“The long-term Cimzia(R) data provide very important information for clinical practitioners treating people with Crohn’s disease,” said study investigator Gary R. Lichtenstein, M.D., professor of medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa. “In clinical trials, Cimzia(R) showed remarkable and sustainable long-term results without the need for dose escalation. Further, patients can achieve long-term symptom relief and remission regardless of the magnitude and rapidity of onset of the initial response.”
Cimzia(R) is the first and only PEGylated anti-TNF (Tumor Necrosis Factor alpha) antibody approved for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2008.
UCB, the manufacturer of Cimzia(R), presented analyses of the PRECiSE 3 and 4 open-label extension studies, which demonstrated the long-term efficacy of Cimzia(R) in treating Crohn’s disease. PRECiSE 3 data showed that eight out of ten patients who were in remission at six months stayed in remission for up to 18 months. Furthermore, 35 percent of patients who had relapsed during PRECiSE 2 but were treated with one additional dose of Cimzia(R) (PRECiSE 4), achieved and maintained remission at six and 12 months with maintenance dosing every 4 weeks and no dose escalation. [Abstract #T1133]
"The DDW meeting marks an exciting time to announce additional long-term data for Cimzia(R), given its recent approval by the FDA,” said Olav Hellebo, Senior Vice President and President of Inflammation Operations, UCB. “UCB remains committed to providing healthcare professionals with effective therapies to improve the lives of patients suffering from this debilitating disease.”
In a related analysis of PRECiSE 2 and 3, the durability of long-term maintenance of response and remission proved not to be related to the rapidity or magnitude of response or remission following induction of Cimzia(R), demonstrating that patients can go on to experience positive response and remission rates regardless of the magnitude and speed of the initial response. [Abstract #T1126]
The pooled data also shows that the PRECiSE Phase 2 and Phase 3 clinical trials showed no unexpected safety findings and no increase in the rate of common adverse events with sustained exposure to Cimzia(R). Results also demonstrate stable dosing in patients taking the medication for more than six months. [Abstract #469]
About the PRECiSE Clinical Trial Program
PRECiSE, one of the largest, most comprehensive development programs for an anti-TNF for Crohn’s disease is composed of two placebo-controlled studies and two open-label safety follow-up studies. In 2007, the two former studies were published in the New England Journal of Medicine (NEJM). The studies demonstrated that patients with moderate to severe Crohn’s disease achieved and sustained clinical response with Cimzia(R) for up to six months, compared to placebo. The safety and tolerability of Cimzia(R) was consistent with that expected of an anti-TNF agent. In the first follow-up study, patients completing both initial studies are to be given Cimzia(R) every four weeks for up to seven years. In the second follow-up study, patients who relapsed in either initial study (defined as an increase in CDAI of >70 or absolute CDAI of >350) were re-introduced to Cimzia(R) every four weeks to be continued for up to seven years, with a single additional dose at week 2.
About Crohn’s Disease
Crohn’s disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). If not effectively treated, it results in the need for surgery. Crohn’s disease has been estimated to affect as many as half a million Americans. People with Crohn’s can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn’s disease is an inflammatory bowel disease (IBD).
About Cimzia(R) (certolizumab pegol)
Cimzia(R) is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF- alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia(R) in Crohn’s disease, rheumatoid arthritis and other autoimmune disease indications. Cimzia(R) is a registered trademark of UCB Inc. For full prescribing information, please visit www.cimzia.com.
UCB News
IMPORTANT SAFETY INFORMATION
Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have been observed in patients receiving Cimzia(R). Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as Cimzia(R). However, active tuberculosis has developed in patients receiving Cimzia(R) whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior to initiating Cimzia(R) and during therapy. Initiate treatment of latent tuberculosis infection prior to therapy with Cimzia(R). Monitor patients receiving Cimzia(R) for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection. Consider anti-tuberculosis therapy prior to initiation of Cimzia(R) in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including Cimzia(R). Infections have been reported in patients receiving Cimzia(R) alone or in conjunction with immunosuppressive agents. Do not initiate treatment with Cimzia(R) in patients with active infections, including chronic or localized infections. Patients who develop a new infection while undergoing treatment with Cimzia(R) should be monitored closely. Discontinue administration of Cimzia(R) if a patient develops a serious infection. Exercise caution when considering the use of Cimzia(R) in patients with a history of recurrent infection, concomitant immunosuppressive therapy, or underlying conditions that may predispose them to infections, or patients who have resided in regions where tuberculosis and histoplasmosis are endemic.
Use of TNF blockers, including Cimzia(R), may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia(R) therapy. Exercise caution in prescribing Cimzia(R) for patients identified as carriers of HBV. Patients who are carriers of HBV and require treatment with Cimzia(R) should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, discontinue Cimzia(R) and initiate effective anti-viral therapy with appropriate supportive treatment.
During controlled and open-labeled portions of Cimzia(R) studies of Crohn’s disease and other investigational uses, malignancies were observed at a rate (95% confidence interval) of 0.6 (0.4, 0.8) per 100 patient-years among 4,650 Cimzia(R)-treated patients verses a rate of 0.6 (0.2, 1.7) per 100 patient-years among 1,319 placebo-treated patients. The size of the control group and limited duration of the controlled portions of the studies preclude the ability to draw firm conclusions. In studies of Cimzia(R) for Crohn’s disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker therapy in the development of malignancies is not known.
UCB
Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia(R) administration. If such reactions occur, discontinue further administration of Cimzia(R) and institute appropriate therapy.
Use of TNF blockers, including Cimzia(R), has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with Cimzia(R); the causal relationship to Cimzia(R) remains unclear. Exercise caution in considering the use of Cimzia(R) in patients with these disorders.
Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with Cimzia(R). The causal relationship of these events to Cimzia(R) remains unclear. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia(R). Consider discontinuation of Cimzia(R) therapy in patients with confirmed significant hematologic abnormalities.
Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of Cimzia(R) and anakinra is not recommended.
Interference with certain coagulation assays has been detected in patients treated with Cimzia(R). There is no evidence that
Cimzia(R) therapy has an effect on in vivo coagulation.
Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia(R) has not been formally studied in patients with CHF. Exercise caution when using Cimzia(R) in patients who have heart failure and monitor them carefully.
Treatment with Cimzia(R) may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.
Do not administer live vaccines or attenuated vaccines concurrently with Cimzia(R).
In controlled Crohn’s clinical trials, the most common adverse events that occurred in ≥5% of Cimzia(R) patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% Cimzia(R), 13% placebo), urinary tract infection (7% Cimzia(R), 6% placebo), and arthralgia (6% Cimzia(R), 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for Cimzia(R) and 7% for placebo.
Cimzia(R) should be administered by a healthcare professional.
About Digestive Disease Week (DDW)
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 17-22, 2008, at the San Diego Convention Center, San Diego, CA. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit www.ddw.org.
About UCB
UCB (Brussels, Belgium) (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on Euronext Brussels.
SOURCE: UCB
Post Views: 81
UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn’s disease
San Diego, CA, USA | May 20, 2008 | UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn’s disease. Data also showed continued remission amongst the majority of responders, and the remission rate remained stable in many of the patients who were re-induced with Cimzia(R). These results represent data from the PRECiSE trial program, which evaluated more than 1,300 patients receiving continuous treatment with Cimzia(R) (400 mg) for up to 18 months.
“The long-term Cimzia(R) data provide very important information for clinical practitioners treating people with Crohn’s disease,” said study investigator Gary R. Lichtenstein, M.D., professor of medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa. “In clinical trials, Cimzia(R) showed remarkable and sustainable long-term results without the need for dose escalation. Further, patients can achieve long-term symptom relief and remission regardless of the magnitude and rapidity of onset of the initial response.”
Cimzia(R) is the first and only PEGylated anti-TNF (Tumor Necrosis Factor alpha) antibody approved for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2008.
UCB, the manufacturer of Cimzia(R), presented analyses of the PRECiSE 3 and 4 open-label extension studies, which demonstrated the long-term efficacy of Cimzia(R) in treating Crohn’s disease. PRECiSE 3 data showed that eight out of ten patients who were in remission at six months stayed in remission for up to 18 months. Furthermore, 35 percent of patients who had relapsed during PRECiSE 2 but were treated with one additional dose of Cimzia(R) (PRECiSE 4), achieved and maintained remission at six and 12 months with maintenance dosing every 4 weeks and no dose escalation. [Abstract #T1133]
"The DDW meeting marks an exciting time to announce additional long-term data for Cimzia(R), given its recent approval by the FDA,” said Olav Hellebo, Senior Vice President and President of Inflammation Operations, UCB. “UCB remains committed to providing healthcare professionals with effective therapies to improve the lives of patients suffering from this debilitating disease.”
In a related analysis of PRECiSE 2 and 3, the durability of long-term maintenance of response and remission proved not to be related to the rapidity or magnitude of response or remission following induction of Cimzia(R), demonstrating that patients can go on to experience positive response and remission rates regardless of the magnitude and speed of the initial response. [Abstract #T1126]
The pooled data also shows that the PRECiSE Phase 2 and Phase 3 clinical trials showed no unexpected safety findings and no increase in the rate of common adverse events with sustained exposure to Cimzia(R). Results also demonstrate stable dosing in patients taking the medication for more than six months. [Abstract #469]
About the PRECiSE Clinical Trial Program
PRECiSE, one of the largest, most comprehensive development programs for an anti-TNF for Crohn’s disease is composed of two placebo-controlled studies and two open-label safety follow-up studies. In 2007, the two former studies were published in the New England Journal of Medicine (NEJM). The studies demonstrated that patients with moderate to severe Crohn’s disease achieved and sustained clinical response with Cimzia(R) for up to six months, compared to placebo. The safety and tolerability of Cimzia(R) was consistent with that expected of an anti-TNF agent. In the first follow-up study, patients completing both initial studies are to be given Cimzia(R) every four weeks for up to seven years. In the second follow-up study, patients who relapsed in either initial study (defined as an increase in CDAI of >70 or absolute CDAI of >350) were re-introduced to Cimzia(R) every four weeks to be continued for up to seven years, with a single additional dose at week 2.
About Crohn’s Disease
Crohn’s disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). If not effectively treated, it results in the need for surgery. Crohn’s disease has been estimated to affect as many as half a million Americans. People with Crohn’s can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn’s disease is an inflammatory bowel disease (IBD).
About Cimzia(R) (certolizumab pegol)
Cimzia(R) is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF- alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia(R) in Crohn’s disease, rheumatoid arthritis and other autoimmune disease indications. Cimzia(R) is a registered trademark of UCB Inc. For full prescribing information, please visit www.cimzia.com.
UCB News
IMPORTANT SAFETY INFORMATION
Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have been observed in patients receiving Cimzia(R). Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as Cimzia(R). However, active tuberculosis has developed in patients receiving Cimzia(R) whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior to initiating Cimzia(R) and during therapy. Initiate treatment of latent tuberculosis infection prior to therapy with Cimzia(R). Monitor patients receiving Cimzia(R) for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection. Consider anti-tuberculosis therapy prior to initiation of Cimzia(R) in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including Cimzia(R). Infections have been reported in patients receiving Cimzia(R) alone or in conjunction with immunosuppressive agents. Do not initiate treatment with Cimzia(R) in patients with active infections, including chronic or localized infections. Patients who develop a new infection while undergoing treatment with Cimzia(R) should be monitored closely. Discontinue administration of Cimzia(R) if a patient develops a serious infection. Exercise caution when considering the use of Cimzia(R) in patients with a history of recurrent infection, concomitant immunosuppressive therapy, or underlying conditions that may predispose them to infections, or patients who have resided in regions where tuberculosis and histoplasmosis are endemic.
Use of TNF blockers, including Cimzia(R), may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia(R) therapy. Exercise caution in prescribing Cimzia(R) for patients identified as carriers of HBV. Patients who are carriers of HBV and require treatment with Cimzia(R) should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, discontinue Cimzia(R) and initiate effective anti-viral therapy with appropriate supportive treatment.
During controlled and open-labeled portions of Cimzia(R) studies of Crohn’s disease and other investigational uses, malignancies were observed at a rate (95% confidence interval) of 0.6 (0.4, 0.8) per 100 patient-years among 4,650 Cimzia(R)-treated patients verses a rate of 0.6 (0.2, 1.7) per 100 patient-years among 1,319 placebo-treated patients. The size of the control group and limited duration of the controlled portions of the studies preclude the ability to draw firm conclusions. In studies of Cimzia(R) for Crohn’s disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia(R)-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. The potential role of TNF blocker therapy in the development of malignancies is not known.
UCB
Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following Cimzia(R) administration. If such reactions occur, discontinue further administration of Cimzia(R) and institute appropriate therapy.
Use of TNF blockers, including Cimzia(R), has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with Cimzia(R); the causal relationship to Cimzia(R) remains unclear. Exercise caution in considering the use of Cimzia(R) in patients with these disorders.
Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with Cimzia(R). The causal relationship of these events to Cimzia(R) remains unclear. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia(R). Consider discontinuation of Cimzia(R) therapy in patients with confirmed significant hematologic abnormalities.
Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of Cimzia(R) and anakinra is not recommended.
Interference with certain coagulation assays has been detected in patients treated with Cimzia(R). There is no evidence that
Cimzia(R) therapy has an effect on in vivo coagulation.
Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia(R) has not been formally studied in patients with CHF. Exercise caution when using Cimzia(R) in patients who have heart failure and monitor them carefully.
Treatment with Cimzia(R) may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.
Do not administer live vaccines or attenuated vaccines concurrently with Cimzia(R).
In controlled Crohn’s clinical trials, the most common adverse events that occurred in ≥5% of Cimzia(R) patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% Cimzia(R), 13% placebo), urinary tract infection (7% Cimzia(R), 6% placebo), and arthralgia (6% Cimzia(R), 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for Cimzia(R) and 7% for placebo.
Cimzia(R) should be administered by a healthcare professional.
About Digestive Disease Week (DDW)
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 17-22, 2008, at the San Diego Convention Center, San Diego, CA. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit www.ddw.org.
About UCB
UCB (Brussels, Belgium) (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on Euronext Brussels.
SOURCE: UCB
Post Views: 81
